Accumulation and Utilization Status of Medicare Data in Taiwan from the
Perspective of Pharmacoeconomic Evaluation

Asina Journal Of Social Pharmacy

Previous Articles Next Articles

Accumulation and Utilization Status of Medicare Data in Taiwan from the Perspective of Pharmacoeconomic Evaluation

Lu Yan 1, Duan Xiaomin 1, Ren Xiaoxiao 2, Sun Lihua 1*

1.School of Business Administration, Shenyang Pharmaceutical University, Shenyang 110016, China; 2.Becton Dickinson Medical Devices (Shanghai) Co. Ltd., Shanghai 200040, China

Online:2016-09-20 Published:2016-11-21
Contact: Sun Lihua, professor. Major research area: pharmacoeconomics, medical investment performance and management, etc. Tel: 024-23986553, E-mail: slh-3632@163.com

Abstract

Abstract: Objective To improve Medicare database and the efficiency of data utilization from pharmacoeconomic evaluation perspective in China by studying and learning from the accumulation and utilization practices of Medicare data in Taiwan. Methods Literature and comparative studies were conducted to introduce the utilization status of Medicare database in China and to analyze National Health Insurance Research Databases (NHIRD) systematically. Results and Conclusion Some suggestions are put forward: (1) perfecting data structure, standardizing database and increasing the completeness and the accuracy of the data; (2) improving the corresponding legal provisions, setting up data application procedures to enhance the efficiency of data obtaining and utilizing.

Key words: pharmacoeconomics, Medicare data, data obtaining, Taiwan

Lu Yan, Duan Xiaomin, Ren Xiaoxiao, Sun Lihua. Accumulation and Utilization Status of Medicare Data in Taiwan from the Perspective of Pharmacoeconomic Evaluation[J]. Asina Journal Of Social Pharmacy.

Trendmd

[1]	Lu Yan, Ren Xiaoxiao, Jia Yaozhu, Sun Lihua. Medical Insurance Data in China from Pharmacoeconomic Evaluation Perspective: Problems and Countermeasures [J]. Asina Journal Of Social Pharmacy, 2016, 11(4): 158-162.
[2]	Duan Xiaomin, Lu Yan, Sun Lihua. Impact of Big Medical Data on Medical Record Data Formation Model from Pharmacoeconomic Evaluation Perspectives [J]. Asina Journal Of Social Pharmacy, 2016, 11(3): 112-115.
[3]	YAN Yong-bo;LI Ye. Application of Pharmacoeconomics to Clinical Trials [J]. , 2012, 7(2): 81-84.
[4]	GUO Ying;YUAN Hong-mei;ZHANG Juan . On Patent Drug Pricing Policy in China [J]. , 2011, 6(4): 203-207.
[5]	WU Hong-yan;SUN Li-hua. The Analysis of Reasons which Restricted the Pharmacoeconomics’ Development in China through the Relationship of Supply and Demand [J]. , 2008, 3(4): 175-178.
[6]	ZENG Hong;WANG Miao;DI Dong-hua;GAO Chong-xiang. Application of Pharmacoeconomics in Social Pharmacy [J]. , 2007, 2(1): 33-37.
[7]	ZHANG Jie. Appling Pharmacoeconomics to Drug Reimbursement Decision-making Process in Canada [J]. , 2006, 1(2): 84-86.
[8]	ZUO Gen-yong;SHAO Rui-qi. Current Advances and existing problem of Pharmacoeconomics in China [J]. , 2006, 1(1): 48-52.
[9]	WU Jing. The Use of Expert Judgement in Pharmacoeconomics [J]. , 2006, 1(1): 26-30.

Asian Journal Of Social Pharmacy

Accumulation and Utilization Status of Medicare Data in Taiwan from the Perspective of Pharmacoeconomic Evaluation

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 9

Recommended Articles

Metrics

Comments